Role of Anti-PAH Drugs in CTEPH
Riociguat is the only approved and recommended anti-PAH drug for CTEPH, specifically indicated for inoperable patients or those with persistent/recurrent pulmonary hypertension after pulmonary endarterectomy (PEA). 1, 2
Treatment Algorithm for CTEPH
The use of anti-PAH drugs in CTEPH follows a clear hierarchy based on surgical candidacy:
1. Primary Assessment: Surgical Candidacy
All CTEPH patients must first be evaluated by an experienced multidisciplinary team including a PEA surgeon to determine operability 1, 2. Pulmonary endarterectomy remains the treatment of choice and is potentially curative 3.
2. Three Specific Indications for Anti-PAH Drugs
Anti-PAH medications are justified in only three scenarios 3:
- Inoperable patients (technically unsuitable for surgery)
- Persistent or residual pulmonary hypertension after PEA
- Unacceptable surgical risk-benefit ratio
3. Specific Drug Recommendations
First-Line Medical Therapy:
- Riociguat (soluble guanylate cyclase stimulator) is the only drug with Class I, Level B recommendation 2
Alternative Options:
- Off-label PAH drugs may be considered (Class IIb, Level B) in inoperable patients, but only after multidisciplinary team assessment 2
- Bosentan (endothelin antagonist) failed to meet its primary endpoint in trials, showing no improvement in 6-minute walk distance despite some hemodynamic benefits 3, 4
- Macitentan showed promise in Phase II trials for inoperable CTEPH 1
Critical Caveats
What NOT to do:
- Do not use anti-PAH drugs as a bridge to surgery in high-risk patients—this is currently not justified 3
- Do not use anti-PAH drugs in patients with chronic thromboembolic disease (CTED) without pulmonary hypertension at rest 1
- Do not prescribe off-label PAH drugs without formal assessment by a CTEPH expert team including an experienced PEA surgeon 2
Essential Baseline Management
Regardless of surgical candidacy, all CTEPH patients require 3, 1, 2:
- Lifelong anticoagulation (vitamin K antagonists; no data on NOACs)
- Diuretics if heart failure present
- Oxygen if hypoxemic
Emerging Considerations
Balloon pulmonary angioplasty (BPA) is increasingly used as an alternative or adjunct to medical therapy for inoperable patients with appropriate target lesions (Class IIb, Level C) 2. The most recent evidence suggests multimodal approaches combining surgery, BPA, and medical therapy are becoming more common in carefully selected patients 5.
The key principle: Medical therapy is never first-line for CTEPH. Surgery must be ruled out first by an expert team, as it offers the only potential cure with dramatic hemodynamic improvements and near-normalization of pulmonary pressures 3.